Feasibility Study of a Portable Artificial Pancreas System in Type 1 Diabetes Mellitus (T1DM) - Padova

Type 1 Diabetes Mellitus Clinical Trial

— HomeCTR1_2  

Official title:

Pilot Study 1 of Outpatient Control-to-Range - System and Monitoring Testing

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01447992
• Other study ID #: 2433P
• Secondary ID: JDRF 22-2011-649
• Status: Completed
• Phase: Phase 0
• First received: September 29, 2011
• Last updated: June 17, 2014
• Start date: September 2011
• Est. completion date: April 2012

Study information

• Verified date: June 2014
• Source: University of Virginia
• Contact: n/a
• Is FDA regulated: No
• Health authority: Italy: Ethics Committee
• Study type: Interventional

Clinical Trial Summary

A single arm, single treatment study is proposed to assess the feasibility of a portable artificial pancreas system outside of a hospital based clinical research center.

Adult T1DM patients will use a newly developed platform in conjunction with a subcutaneous insulin infusion pump and a continuous glucose monitor for 18 hours is quasi free conditions (hotel).

Description:

Automated closed-loop control (CLC), known as "artificial pancreas" (AP) can have tremendous impact on the health and lives of people with type 1 diabetes (T1D). Our inter-institutional and international research team has been on the forefront of CLC developments since the beginning of the Juvenile Diabetes Research Foundation (JDRF) Artificial Pancreas initiative in 2006. Thus far, we have conducted three closed-loop control clinical trials (totaling 60 subjects with T1D), which demonstrated significantly more time in an acceptable "target" blood glucose range during CLC, and significantly fewer hypoglycemic events during CLC compared to open loop. Our overall objective is to sequentially test, validate, obtain regulatory approval for, and deploy at home, a closed-loop Control-to-Range (CTR) system comprised of two algorithmic components: a Safety Supervision Module (SSM) and an automated Range Correction Module (RCM). The SSM will monitor the safety of the subject's continuous subcutaneous insulin infusion pump (CSII) to prevent hypoglycemia, and will also monitor the integrity of continuous glucose monitor (CGM) data for signal sensor deviations or loss of sensitivity. The RCM will be responsible for the optimal regulation of postprandial hyperglycemic excursions through correction boluses.

The first phase to address our overall objective is a pilot study that will test the ability of a cell-phone-based system to (1) run CTR in an outpatient setting, and (2) be remotely monitored. Specifically, this pilot study entails a hybrid hotel/hospital design targeting adults with T1D that are experienced insulin pump users. Subjects will spend one night in a local hotel, during which the phone-based system will be remotely monitored in an adjacent hotel room for validation that remote system monitoring can successfully occur. Subjects will spend the following day in the hospital, where CTR will be activated, and challenged with meals and a CGM sensor replacement . Subjects will then spend a second night in the hotel for continued evaluation of remote system monitoring, along with outpatient testing of the CTR system run on the phone-based system. This series of admissions will address the first major hurdles that need to be overcome for home deployment of a closed loop CTR system:

Specific Aim 1: The phone-based CTR system can be remotely monitored by nurses/physicians/technicians to confirm appropriate functioning outside of the hospital setting.

Specific Aim 2: The CTR can be deployed outside of the hospital setting.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 5
• Est. completion date: April 2012
• Est. primary completion date: April 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 21 Years to 65 Years

Eligibility

Inclusion Criteria:

• Patient must be aged between 21 (inclusive) and 65 years old. The age of 21 has been chosen because this trial is supported by a US Foundation.

• Patient must have been clinically diagnosed with Type 1 diabetes mellitus. For an individual to be enrolled at least one criterion from each list must be met:

• Criteria for documented hyperglycemia (at least 1 must be met):

• Fasting glucose =126 mg/dL - confirmed

• Two-hour Oral Glucose Tolerance Test (OGTT) glucose =200 mg/dL - confirmed

• HbA1c =6.5% documented - confirmed

• Random glucose =200 mg/dL with symptoms

• No data at diagnosis is available but the participant has a convincing history of hyperglycemia consistent with diabetes

• Criteria for requiring insulin at diagnosis (1 must be met):

• Participant required insulin at diagnosis and continually thereafter

• Participant did not start insulin at diagnosis but upon investigator review likely needed insulin (significant hyperglycemia that did not respond to oral agents) and did require insulin eventually and used continually

• Participant did not start insulin at diagnosis but continued to be hyperglycemic, had positive islet cell antibodies - consistent with latent autoimmune diabetes in adults (LADA) and did require insulin eventually and used continually

• Use of an insulin pump to treat his/her diabetes for at least 1 year

• Actively using a carbohydrate (CHO) / insulin ratio for insulin bolus adjustments in order to keep blood glucose in a predefined range

• Patient HbA1c is between 6.0% and 9% as measured with DCA2000 or equivalent device

• Patient must demonstrate proper mental status and cognition for the study

• Patient must be willing to avoid consumption of acetaminophen-containing products during the study interventions involving DexCom use

• Patient must be affiliated or beneficiary of a social medical insurance

• Patient has signed informed consent form prior to study entry

Exclusion Criteria:

• Diabetic ketoacidosis within the 6 months prior to enrollment

• Severe hypoglycemia resulting in seizure or loss of consciousness in the 12 months prior to enrollment

• Pregnancy, breast feeding, or intention of becoming pregnant

• Uncontrolled arterial hypertension (diastolic blood pressure >90 mmHg and/or systolic blood pressure >160 mmHg)

• Conditions which may increase the risk of hypoglycemia such as uncontrolled coronary artery disease during the previous year (e.g. history of myocardial infarction, acute coronary syndrome, therapeutic coronary intervention, coronary bypass or stenting procedure, stable or unstable angina, episode of chest pain of cardiac etiology with documented EKG changes, or positive stress test or catheterization with coronary blockages >50%), congestive heart failure, history of cerebrovascular event, seizure disorder, syncope, adrenal insufficiency, neurologic disease or atrial fibrillation

• History of a systemic or deep tissue infection with methicillin-resistant staph aureus or Candida albicans

• Use of a device that may pose electromagnetic compatibility issues and/or radiofrequency interference with the DexCom CGM (implantable cardioverter-defibrillator, electronic pacemaker, neurostimulator, intrathecal pump, and cochlear implants)

• Anticoagulant therapy other than aspirin

• Oral steroids

• Medical condition requiring use of an acetaminophen-containing medication that cannot be withheld for the study admissions.

• Psychiatric disorders that would interfere with study tasks (e.g. inpatient psychiatric treatment within 6 months prior to enrollment)

• Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation

• Known current or recent alcohol or drug abuse

• Medical conditions that would make operating a CGM, cell phone, or insulin pump difficult (e.g. blindness, severe arthritis, immobility)

• Any skin condition that prevents sensor or pump placement on the abdomen or arm (e.g. bad sunburn, pre-existing dermatitis, intertrigo, psoriasis, extensive scarring, cellulitis)

• Impaired hepatic function measured as alanine aminotransferase or aspartate aminotransferase =three times the upper reference limit

• Impaired renal function measured as creatinine >1.2 times above the upper limit of normal

• Uncontrolled microvascular (diabetic) complications (other than diabetic non-proliferative retinopathy), such as history of laser coagulation, proliferative diabetic retinopathy, known diabetic nephropathy (other than microalbuminuria with normal creatinine) or neuropathy requiring treatment

• Active gastroparesis requiring current medical therapy

• If on antihypertensive, thyroid, anti-depressant or lipid lowering medication, lack of stability on the medication for the past 2 months prior to enrollment in the study

• Uncontrolled thyroid disease

• Known bleeding diathesis or dyscrasia

• Known allergy to medical adhesives, components of the insulin pump insertion set or continuous glucose monitor sensor

• Unwillingness to withhold dietary supplements two weeks prior to admission and for the duration of the study participation.

• Unwillingness to withhold pramlintide, liraglutide and exenatide for the duration of the study intervention.

• Patient is actively enrolled in another clinical trial or was part of study within 30 days or whose annual study income is over 4 500€

• Persons deprived of freedom, adults protected by law or vulnerable persons

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 1
• Type 1 Diabetes Mellitus

Intervention

Device:
• Portable artificial pancreas system with Control-To-Range
We will test the new portable Control-To-Range system in clinical research center conditions for 10 hours followed by 18 hours of Control-To-Range in a hotel.

Locations

Country	Name	City	State
Italy	Azienda Ospedaliera E Universita Degli Study Di Padova	Padova	Veneto

Sponsors (4)

Lead Sponsor	Collaborator
University of Virginia	University Hospital, Montpellier, University of California, Santa Barbara, University of Padova

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	estimation of the failure rates of system components	we will estimate the relative frequency of failures (#failures/opportunity of failure) of each following system components: CGM communication (1 failure opportunity every 5min), pump communication (1 failure opportunity every 5min), insulin dose computation (1 failure opportunity every 5min), user interface (1 failure opportunity every 1min).	length of admission (hour 42)	Yes
Secondary	frequency analysis of lost or inaccurate CGM records	number of CGM data points not received (or corrupted) by the device divided by the total number of possible CGM data points to be received.	length of admission (42 hours)	No
Secondary	percent time of active CTR	number of minutes the Control-To-Range system was functioning properly (computation of insulin infusion, and insulin actually delivered) divided by the maximum number of minutes the CTR system should have been active (as per protocol)	length of admission (42h)	No